Extracorporeal Shock Wave Therapy Market by Type (Mobile Shock Wave Therapy Devices, Fixed Shock Wave Therapy Devices), by Technology (Electromagnetic Technique, Electrohydraulic Technique, Piezoelectric Technique, Radial Technique), by Application (Kidney Stones, Pancreatic Stones, Uretic Stones, Salivary Stones, Musculoskeletal Disorders), by End-user (Hospitals, Physiotherapy Centres, Ambulatory Surgical Centres,Clinics, Radiology Labs, Others) and Geography

 

Extracorporeal Shock Wave Therapy Market size was estimated at USD 102.24 million in 2021, growing at a CAGR of 6.3% during the forecast period 2022-2028. Extracorporeal Shock Wave Therapy Market (ESWT) is developed for the treatment of gall and kidney stones. Extracorporeal shock wave therapy has been used to treat rise in number of musculoskeletal conditions, like rotator cuff tendinitis, tennis elbow, patellar tendinopathy, plantar fasciitis, bony non-unions and Achilles tendinopathy. Shock wave therapy devices are non-invasive treatment for the musculoskeletal pain and can be used frequently in urology, physiotherapy, sports medicine, veterinary medicine and orthopaedics. It is also called as Extracorporeal Shock Wave Therapy (ESWT). Abrupt, high amplitude mechanical energy pulses are generated with help of the electromagnetic coil to manage and reduce the pain in ESWT process. ESWT is an alternative for surgery and also helps in speedy recovery of patients who are suffering from various tendon, muscle and joint disorders. Extracorporeal Shock Wave Therapy (ESWT) market is expected to register a significant CAGR over a forecast period. As the sports-related injuries are common issues, ESWT market has gained more popularity by the sport clinicians and athletes. ESWT devices have received FDA-approval for lateral epicondylitis and plantar fasciitis. According to Health and Safety Executive, the UK, 41% of ill health was encountered among the UK employees due to work-related musculoskeletal disorders (WRMSD), accounting for around 1,311,000 cases in 2014. Furthermore, as per to the Centre for Disease Control about 22.7% of adults are diagnosed with various kind of arthritis, which is accounting around 54.4 million cases from 2013-2015. The high prevalence rate of musculoskeletal disorders creates a highly conducive environment for growth of shock wave therapy devices market.

Key Developments:

In 2003, OssaTron by HealthTronics, Inc., Marietta, GA, USA was approved to treat chronic heel pain In 2001, Dornier Epos Ultra by Dornier Medical Systems, Inc., Kennesaw, GA, USA was approved for treatment of chronic plantar fasciitis for patients with symptoms of plantar fasciitis for 6 months or more and a history of unsuccessful conservative therapy In 2002, Siemens SONOCUR Basic by Siemens Medical Solutions, Inc., Iselin, NJ, USA was approved for treatment of pain due to tennis elbow